jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2019-11-2-20-25jofin-879Research ArticleОбзорReviewКожный лейшманиоз и сопутствующие тканевые гельминтозы (обзор)Cutaneous leishmaniasis and related tissue helminthiasis (review)АхмедоваМ. Д.AkhmedovaM. D.

Ахмедова Мубарахон Джалиловна – профессор кафедры инфекционных и детских инфекционных болезней 

Ташкент

tmainfection@mail.ruАнваровЖ. А.AnvarovJ. A.

Анваров Жахонгир Абралович – ассистент кафедры инфекционных и детских инфекционных болезней 

Ташкент

anvarov_jakhongir@mail.ruСувонкуловУ. Т.SuvonkulovU. T.

Сувонкулов Уктам Таирович – директор Научно-исследовательского института медицинской паразитологии им. Л.М. Исаева, кандидат медицинских наук 

Самарканд

uktam_suvonkulov@mail.ruМирзажоноваД. Б.MirzajonovaD. B.

Мирзажонова Донохон Баходировна – научный сотрудник, кандидат медицинских наук

Ташкент

tmainfection@mail.ruОсиповаС. О.OsipovaS. O.

Осипова Светлана Олеговна – заведующая лаборатории «Коллекция грибов – возбудителей микозов человека», доктор медицинских наук

Ташкент

svetosip7@mail.ruТашкентская медицинская академияУзбекистанTashkent medical academyUzbekistanНаучно-исследовательский институт медицинской паразитологии им. Л.М. ИсаеваУзбекистанScience Research Institute of Medical Parasitology named after L.M. IsaevUzbekistanНаучно-исследовательский институт эпидемиологии, микробиологии и инфекционных заболеванийУзбекистанResearch Institute of epidemiology, microbiology and infectious diseasesUzbekistan2019160520191122025Copyright © Ахмедова М.Д., Анваров Ж.А., Сувонкулов У.Т., Мирзажонова Д.Б., Осипова С.О., 20192019Ахмедова М.Д., Анваров Ж.А., Сувонкулов У.Т., Мирзажонова Д.Б., Осипова С.О.Akhmedova M.D., Anvarov J.A., Suvonkulov U.T., Mirzajonova D.B., Osipova S.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/879

Рассматриваются вопросы эпидемиологии кожного лейшманиоза (КЛ), заболеваемость КЛ остаётся высокой, в Узбекистане отмечается ее рост. Применяемые в лечении лейшманиоза препараты пятивалентной сурьмы токсичны, к ним быстро растет резистентность. Амфотерицин В также токсичен и имеет множество противопоказаний и побочных эффектов. Предполагается, что позитивное влияние могут оказать препараты не только с лейшманицидным действием, но и с репаративными и антиоксидантными свойствами. Анализируется протективный иммунитет при КЛ, опосредованный Th1-ответом. Обсуждается целесообразность обследования больных КЛ на гельминтозы, индуцирующие оппозитный Th2-ответ, и работы по изучению влияния сопутствующих гельминтозов на течение КЛ.

Epidemiology of cutaneous leismaniasis is considered, CL morbidity remains rather high and it is increasing in Uzbekistan. The main medicines in leishmaniasis treatment are pentavalent antimonials which are characterized by toxicity and resistance development, and amphotericin B. Amphotericin B is toxic too and has a lot of contraindications and side effects. Medicines with reparative and antioxidant properties are assumed to positively influence the CL course, not only leishmanicidal preparations. Protective immunity in CL mediated by Th1 response is analyzed. Expediency of examination of patients with CL for helminthiases inducing opposite Th2-response as well as studies of concomitant helminthiases influence on the CL course are discussed.

 

кожный лейшманиозлейшманияиммунный ответцитокинытканевые гельминтозыcutaneous leishmaniasisleishmaniaimmune responsecytokinesparasitosisReferencesKaye P., Scott P. Leishmaniasis: complexity at the hostpathogen interface. Nat. Rev. Microbiol. 2011. 9: 604–615.Kaye P., Scott P. Leishmaniasis: complexity at the hostpathogen interface. Nat. Rev. Microbiol. 2011. 9: 604–615.Лейшманиоз. – Публикация ВОЗ. – № 375. – 2014.Lejshmanioz. Publikacija VOZ №375. 2014. (in Russian).Cергиев, В.П. Паразитарные болезни человека / В.П. Cергиев, Ю.В. Лобзин, С.С. Козлов. – СПб.: Фолиант, 2011. – 608 с.Cergiev, V.P. Parazitarnye bolezni cheloveka / Cergiev V.P., Lobzin Ju.V., Kozlov S.S. – SPb.: Foliant, 2011. – 608 s. (in Russian).Berman J.D. Human leishmaniasis: clinical, diagnostic and chehemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 1997; 24:684-703.Berman J.D. Human leishmaniasis: clinical, diagnostic and chehemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 1997; 24:684-703.Chakravarty J., Sundar S. Drug resistance in leishmaniasis. J. Glob. Infect. Dis. 2010; 2(2):167-176.Chakravarty J., Sundar S. Drug resistance in leishmaniasis. J. Glob. Infect. Dis. 2010; 2(2):167-176.Kunzler B. Cutaneous leishmaniasis: the efficacy of nonantimony treatment in the austere environment. Using cryotherapy, thermotherapy and photodynamic therapy as an alternative method of treatment. J. Spec. Oper. Med. 2013; 13(4):4045.Kunzler B. Cutaneous leishmaniasis: the efficacy of nonantimony treatment in the austere environment. Using cryotherapy, thermotherapy and photodynamic therapy as an alternative method of treatment. J. Spec. Oper. Med. 2013; 13(4):4045.Страчунский, Л.С. Практическое руководство по антиинфекционной терапии / Л.С. Страчунский, Ю.Б. Белоусов, С.Н. Козлов. – НИИАХ СГМА, 2007. – 420 с.Strachunskij, L.S. Prakticheskoe rukovodstvo po antiinfekcionnoj terapii / Strachunskij L.S., Belousov Ju.B., Kozlov S.N. 2007. – 420 s. (in Russian).Savoia D. Recent updates and perspectives on leishmaniasis. J Infect Dev Ctries. 2015 Jul 4;9(6):588-96.Savoia D. Recent updates and perspectives on leishmaniasis. J Infect Dev Ctries. 2015 Jul 4;9(6):588-96.Taheri A.R., Govonlo V.M., Nahidi Y. et al. Plasma levels of interleukin-4 and interferon-γ in patients with chronic or healed cutaneous leishmaniasis. Iran J. Basic Med. Sci. 2014; Mar; 17 (3):216-219.Taheri A.R., Govonlo V.M., Nahidi Y. et al. Plasma levels of interleukin-4 and interferon-γ in patients with chronic or healed cutaneous leishmaniasis. Iran J. Basic Med. Sci. 2014; Mar; 17 (3):216-219.Valencia C., Arévalo J., Dujardin J.C. et al. Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions. PLoS Negl Trop Dis. 2012; 6(6): e1656. doi: 10.1371/journal.pntd.0001656. Epub 2012.Valencia C., Arévalo J., Dujardin J.C. et al. Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions. PLoS Negl Trop Dis. 2012; 6(6): e1656. doi: 10.1371/journal.pntd.0001656. Epub 2012.Шуйкина, Э.Е. Возможность антибиотикотерапии при лейшманиозах / Э.Е. Шуйкина [и др]. // Мед. паразитол. – 2009. – № 3, – С. 45–47.Shujkina, Je.E. Vozmozhnost’ antibiotikoterapii pri lejshmaniozah / Shujkina Je.E., Kurdina M.I., Kurbatova I.V. i soavt. // Med. parazitol. – 2009. – № 3, – S. 45-47. (in Russian).Rezaei Riabi T., Sharifi I., Miramin Mohammadi A., Khamesipour A . et al. Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate. Iran J Parasitol. 2013 Jul;8(3):396-401.Rezaei Riabi T., Sharifi I., Miramin Mohammadi A., Khamesipour A . et al. Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate. Iran J Parasitol. 2013 Jul;8(3):396-401.Barbosa J.F., de Figueiredo S.M., Monteiro F., et al. New Approaches on Leishmaniasis Treatment and Prevention: A Review on Recent Patents. Recent Pat. Endocr. Metab. Immune Drug Discov. 2015 Sep 21.Barbosa J.F., de Figueiredo S.M., Monteiro F., et al. New Approaches on Leishmaniasis Treatment and Prevention: A Review on Recent Patents. Recent Pat. Endocr. Metab. Immune Drug Discov. 2015 Sep 21.Moreno E., Schwartz J., Fernandez C. et al. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis. Expert Opinion on Drug Delivery. 2014. –Vol.11, N 4. – 579-597.Moreno E., Schwartz J., Fernandez C. et al. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis. Expert Opinion on Drug Delivery. 2014. –Vol.11, N 4. – 579-597.Croft S.L., Olliaro P. Leishmaniasis chemotherapy – challenges and opportunities. Clin. Microbiol. Infect. 2011. 17 (10): 1478-1483.Croft S.L., Olliaro P. Leishmaniasis chemotherapy – challenges and opportunities. Clin. Microbiol. Infect. 2011. 17 (10): 1478-1483.Mock D.J., Hollenbaugh J.A., Daddacha W. et al. Leishmania induces surviuval, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration pf HIV-co-infection. PloS Pathog. 2012; 8(4):e1002635Mock D.J., Hollenbaugh J.A., Daddacha W. et al. Leishmania induces surviuval, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration pf HIV-co-infection. PloS Pathog. 2012; 8(4):e1002635Olliaro P., Vaillant M., Arana B. et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis. 2013;7(3):e2130. doi: 10.1371/journal.pntd.0002130. Epub 2013 Mar 21.Olliaro P., Vaillant M., Arana B. et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis. 2013;7(3):e2130. doi: 10.1371/journal.pntd.0002130. Epub 2013 Mar 21.Arimand R., Fard S., Saberi S., et al. Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Adv Biomed Res. 2015; 4: 128.Arimand R., Fard S., Saberi S., et al. Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Adv Biomed Res. 2015; 4: 128.Matos I., Mizenina O., Lubkin A. et al. Targeting Leishmania major antigens to dendritic cells in vivo induces protective immunity. PLoS one, 2013; 8(6): e67453.Matos I., Mizenina O., Lubkin A. et al. Targeting Leishmania major antigens to dendritic cells in vivo induces protective immunity. PLoS one, 2013; 8(6): e67453.Tripathi P., Singh V., Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol 2007; 51: 229–242.Tripathi P., Singh V., Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol 2007; 51: 229–242.Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Ann Rev Immunol. 1995; 13:151-177.Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Ann Rev Immunol. 1995; 13:151-177.Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2: 845–858.Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2: 845–858.Scott P., Artis D., Uzonna J., Zaph C. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development// Immunol Rev. 2004; 201: 318–338.Scott P., Artis D., Uzonna J., Zaph C. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development// Immunol Rev. 2004; 201: 318–338.Launois P., Louis J.A., Milon G. The fate and persistence of Leishmania major in mice of different genetic backgrounds: an example of exploitation of the immune system by intracellular parasites. Parasitology. 1997; 115 Suppl: S25–S32Launois P., Louis J.A., Milon G. The fate and persistence of Leishmania major in mice of different genetic backgrounds: an example of exploitation of the immune system by intracellular parasites. Parasitology. 1997; 115 Suppl: S25–S32Costa D.L., Carregaro V., Lima-Júnior D.S., et al. BALB/cmice infected with antimony treatment refractory isolate of Leishmania braziliensis present severe lesions due to IL-4 production. PLoS Negl Trop Dis. 2011 Mar 1;5(3):e965.Costa D.L., Carregaro V., Lima-Júnior D.S., et al. BALB/cmice infected with antimony treatment refractory isolate of Leishmania braziliensis present severe lesions due to IL-4 production. PLoS Negl Trop Dis. 2011 Mar 1;5(3):e965.Lazarski Ch.A., Ford J., Katzman Sh.D. et al., IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PloS One. 2013; 8 (8): e71949.Lazarski Ch.A., Ford J., Katzman Sh.D. et al., IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PloS One. 2013; 8 (8): e71949.Schwarz T., Remet K., Nahrendorf W. et al. T-cell derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine. PLOS Pathog. 2013; 9(56): e1003-476.2013).Schwarz T., Remet K., Nahrendorf W. et al. T-cell derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine. PLOS Pathog. 2013; 9(56): e1003-476.2013).Neumayr A.L., Morizot G., Visser L.G. et al. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with INF-α antagonists. Travel Med. Infect. Dis. 2013; 11(6):412-420.Neumayr A.L., Morizot G., Visser L.G. et al. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with INF-α antagonists. Travel Med. Infect. Dis. 2013; 11(6):412-420.Lessa H.A., Machado P., Lima F. et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg. 2001 Aug; 65(2):87-89.Lessa H.A., Machado P., Lima F. et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg. 2001 Aug; 65(2):87-89.Almeida R.P., Brito J., Machado P.R. et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Amer. J. Trop. Med. Hyg. 2005; 73(1): 79081.Almeida R.P., Brito J., Machado P.R. et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Amer. J. Trop. Med. Hyg. 2005; 73(1): 79081.Santos J.B., de Jesus A.R., Machado P.R. et al. Antimony plus recombinant human granulocyte-macrophage colonystimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis. 2004 Nov 15;190(10):1793-6. Epub 2004 Oct 18.Santos J.B., de Jesus A.R., Machado P.R. et al. Antimony plus recombinant human granulocyte-macrophage colonystimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis. 2004 Nov 15;190(10):1793-6. Epub 2004 Oct 18.Alexander J, Bryson K. T helper (h) 1/Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 2005 Jun 15; 99(1):17-23.Alexander J, Bryson K. T helper (h) 1/Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 2005 Jun 15; 99(1):17-23.Сastellano L.R., Filho D.C., Argiro L., Dessein H., Prato A., Dessein A., et al. Th1/Th2 immune responses are associated with active cutaneous Leishmaniasis and clinical cure is associated with strong interferon – gamma production. Hum immunol. 2009; 99:17-23.Сastellano L.R., Filho D.C., Argiro L., Dessein H., Prato A., Dessein A., et al. Th1/Th2 immune responses are associated with active cutaneous Leishmaniasis and clinical cure is associated with strong interferon – gamma production. Hum immunol. 2009; 99:17-23.Choi B.S., Kropf P. Evaluation of T cell responses in healing and nonhealing Leishmaniasis reveals difference in T helper cell polarization ex vivo and vitro. Parasite Immunol. 2009; 31:199-209.Choi B.S., Kropf P. Evaluation of T cell responses in healing and nonhealing Leishmaniasis reveals difference in T helper cell polarization ex vivo and vitro. Parasite Immunol. 2009; 31:199-209.Harms G., Zwinngenberger K., Chahade A.K. et al. Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet. 1989; 1(8650): 1287-1292.Harms G., Zwinngenberger K., Chahade A.K. et al. Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet. 1989; 1(8650): 1287-1292.Haas N., Hauptmann S., Paralikoudi D. et al. Interferongamma treatment induces granulomatous tissue reactions in a case of localized cutaneous leishmaniasis. Am. J. Dermatopathol. 2002, Aug; 24 (4):319-323.Haas N., Hauptmann S., Paralikoudi D. et al. Interferongamma treatment induces granulomatous tissue reactions in a case of localized cutaneous leishmaniasis. Am. J. Dermatopathol. 2002, Aug; 24 (4):319-323.Ajdary S., Riazi–Rad F., Alihomommadian M.H. et al. Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis. Parasite Imunol. 1999; 21: 423-431.Ajdary S., Riazi–Rad F., Alihomommadian M.H. et al. Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis. Parasite Imunol. 1999; 21: 423-431.Anthony R.M., Rutitzky LK.I., Urban J.F. et al. Protective immune mechanisms in helminth infection. Nat. Rev. Immunol. 2007; 7; 975-987.Anthony R.M., Rutitzky LK.I., Urban J.F. et al. Protective immune mechanisms in helminth infection. Nat. Rev. Immunol. 2007; 7; 975-987.Maizels R., Hewitson J.P., Smith K. Susceptibility and immunity to helminth parasites. Current Opinion in Immunology. 2012; 24: 459-466.Maizels R., Hewitson J.P., Smith K. Susceptibility and immunity to helminth parasites. Current Opinion in Immunology. 2012; 24: 459-466.McKee A.S., Pearce E.J. CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol. 2004; Jul 15;173(2):1224-31.McKee A.S., Pearce E.J. CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol. 2004; Jul 15;173(2):1224-31.Rodriguez-Sosa M., Rivera-Montiya I., Espinosa A. et al. Acute cysticercosis favors rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternative activated macrophages. Cell. Immnuol. 2006; 242(2):61-71.Rodriguez-Sosa M., Rivera-Montiya I., Espinosa A. et al. Acute cysticercosis favors rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternative activated macrophages. Cell. Immnuol. 2006; 242(2):61-71.La Flamme A.C., Scott P., Pearce E.J. Schistosomiasis delays lesion resolution during Leishmania major infection by impairing parasite killing macrophages. Parasite Immunol. 2002; 24 (7): 339-345.La Flamme A.C., Scott P., Pearce E.J. Schistosomiasis delays lesion resolution during Leishmania major infection by impairing parasite killing macrophages. Parasite Immunol. 2002; 24 (7): 339-345.O’Neill S.E., Guimaraes L.H., Machado P.R. et al. Influence of Helminth infections on the clinical course of and immune response to Leishmania brasiliensis cutaneous leishmaniasis. J. Infectious Dis. 2007. – Vol. 195, issue 1. P. 142-148.O’Neill S.E., Guimaraes L.H., Machado P.R. et al. Influence of Helminth infections on the clinical course of and immune response to Leishmania brasiliensis cutaneous leishmaniasis. J. Infectious Dis. 2007. – Vol. 195, issue 1. P. 142-148.Bafica A.M., Cardoso L., Oliveira S.C. et al. Schistosoma mansini antigens alter the cytokine response in-vitro during cutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz. 2011; 106 (7): 8565-863.Bafica A.M., Cardoso L., Oliveira S.C. et al. Schistosoma mansini antigens alter the cytokine response in-vitro during cutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz. 2011; 106 (7): 8565-863.Kolbaum J., Ritter R., Zimara N. et al. Efficient control of Leishmania and Strongyloides despite partial suppression nematode-induced Th2-response in co-infected mice. Parasite Immunol. 2011; 33(4):226-235.Kolbaum J., Ritter R., Zimara N. et al. Efficient control of Leishmania and Strongyloides despite partial suppression nematode-induced Th2-response in co-infected mice. Parasite Immunol. 2011; 33(4):226-235.Yoshida A., Maruyama H., Yabu Y. et al. Immune response against proitozoal and nemadodal infection in mice with underlying Schistosoma mansoni infection. Parasitol. Int. 1999; 48; (1):73-79.Yoshida A., Maruyama H., Yabu Y. et al. Immune response against proitozoal and nemadodal infection in mice with underlying Schistosoma mansoni infection. Parasitol. Int. 1999; 48; (1):73-79.Newlove T., Guimaraes L.H., Morgan D.J. et al. Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with Helminths and Leishmania brasiliensis. Am. J. Trop. Med. Hyg. 2011; 84 (4):551-555.Newlove T., Guimaraes L.H., Morgan D.J. et al. Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with Helminths and Leishmania brasiliensis. Am. J. Trop. Med. Hyg. 2011; 84 (4):551-555.

The authors declare that there are no conflicts of interest present.